Literature DB >> 19634077

Pathology of pulmonary arterial hypertension.

Rubin M Tuder1.   

Abstract

The pathological features of pulmonary arterial hypertension are highlighted in this review, which can serve as a guide to diagnosis and identification of potential cellular targets for novel lines of therapy. It also emphasizes the variability of pathological processes found in pulmonary hypertensive lungs collected by the Pulmonary Breakthrough Initiative of the Cardiovascular Medical Research Fund. This initiative is aimed at banking properly phenotyped lung tissue and implementing relevant human lung-based investigations of pulmonary arterial hypertension. This effort has led to an insight of site-specific heterogeneity of relevant pulmonary vascular pathologies and how associated histopathological processes, including interstitial fibrotic and inflammatory findings, may need to be considered in the development of future therapies. We also highlight the pulmonary vascular pathology in schistosomiasis-associated pulmonary arterial hypertension, possibly the most frequent cause of pulmonary hypertension worldwide.

Entities:  

Mesh:

Year:  2009        PMID: 19634077     DOI: 10.1055/s-0029-1233307

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  44 in total

1.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

2.  Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.

Authors:  Wanli Ma; Weihong Han; Peter A Greer; Rubin M Tuder; Haroldo A Toque; Kevin K W Wang; R William Caldwell; Yunchao Su
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

Review 3.  The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Authors:  Jeffrey C Robinson; Brian B Graham; Tracey C Rouault; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

4.  Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.

Authors:  Lloyd D Harvey; Stephen Y Chan
Journal:  J Physiol       Date:  2018-09-02       Impact factor: 5.182

5.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

6.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01

Review 7.  Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.

Authors:  Brian B Graham; Angela Pontes Bandeira; Nicholas W Morrell; Ghazwan Butrous; Rubin M Tuder
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 8.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

Review 9.  The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.

Authors:  Yasunobu Hayabuchi
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

Review 10.  Vascular remodeling in pulmonary hypertension.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Mol Med (Berl)       Date:  2013-01-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.